Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genzyme’s Head of Rare Diseases Honored by the Genetic Disease Foundation

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Rogerio Vivaldi MD receives Industry Person of the Year.

Genzyme’s Head of Rare Diseases, Rogerio Vivaldi, MD, has been honored as the Genetic Disease Foundation’s Industry Person of the Year. The award is given to an individual in the life sciences industry who has made outstanding contributions to advancing medical research and bringing new therapies to people living with rare genetic diseases.

“For more than 20 years, Dr. Vivaldi has worked to identify the unmet needs of those living with rare genetic diseases, such as Gaucher disease,” said Elisa Ross, President of the Genetic Disease Foundation (GDF). “We are pleased to recognize Dr. Vivaldi for his dedication and commitment to improving patients’ lives.”

The award will be presented tonight at the GDF Gala at New York’s Gotham Hall. The event will raise funds for the Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai.

“I am truly honored by this award. As a physician in Brazil, I saw firsthand the importance of diagnosis and treatment for rare genetic diseases,” said Dr. Vivaldi. “At Genzyme we continue the mission to develop and deliver transformative therapies to all patients affected by rare genetic diseases.”

The Genetic Disease Foundation is a non-profit organization established in 1997 by patients and families affected by genetic disorders. The Foundation’s mission is to help prevent and treat genetic diseases by supporting research and counseling and conducting educational initiatives.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA™ for Multiple Sclerosis
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare.
Wednesday, June 13, 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement
The companies announced the partnership will provide personalized and comprehensive solution for thyroid patients.
Monday, January 23, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Senor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Investigating ‘Black Box’ of Human Genetics
Investigations into inactive X chromosomes have shown unusual DNA repeat elements are essential for maintaining 3D structure.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!